Merck & Co. Inc.
NYS : MRK
Pharmaceuticals
Whitehouse Station NJ
Pharmaceuticals
Whitehouse Station NJ
| Current Rank Rank | 28 |
| Prior Rank | 27 |
| Executive 1 | Kenneth Frazier, Chairman; President; Chief Executive Officer |
| Executive 2 | Peter N. Kellogg, Chief Financial Officer |
| IW Best50 | N/A |
| 2012 Revenue (US$ Millions) | $47,267 |
| 2011 Revenue (US$ Millions) | $48,047 |
| Revenue Growth (%) | -1.62% |
| Net Income (US$ Millions) | $6,168 |
| Common Shares Outstanding (Millions) | $3,027 |
| Earnings Per Share (US$) | $2.00 |
| Total Equity (US$ Millions) | $53,020 |
| Profit Growth (%) | -1.66 |
| Profit Margin (%) | 13.05% |
| Return On Equity (%) | 11.31% |
| Long Term Debt (US$ Millions) | $16,254 |
| Debt To Equity Ratio (%) | 0.31% |
| Market Capitalization (US$ Millions) | $123,910 |
| Total Assets (US$ Millions) | $106,132 |
| Return on Assets (%) | 5.87 |
| Current Assets (US$ Millions) | $34,857 |
| Inventories (US$ Millions) | $6,535 |
| Current Liabilities (US$ Millions) | $18,348 |
| Cost of Goods Sold (US$ Millions) | $16,446 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 2.57 |